Free Trial

Danaher Corporation (NYSE:DHR) Shares Purchased by State of Alaska Department of Revenue

Danaher logo with Medical background

State of Alaska Department of Revenue boosted its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 2.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 75,004 shares of the conglomerate's stock after acquiring an additional 1,717 shares during the period. State of Alaska Department of Revenue's holdings in Danaher were worth $15,375,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Norges Bank purchased a new stake in shares of Danaher in the fourth quarter valued at approximately $2,130,740,000. GAMMA Investing LLC grew its holdings in Danaher by 24,958.2% in the 1st quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock valued at $383,524,000 after buying an additional 1,863,381 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Danaher in the 4th quarter valued at $391,172,000. Two Sigma Advisers LP increased its stake in shares of Danaher by 4,248.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock worth $376,347,000 after acquiring an additional 1,601,800 shares during the last quarter. Finally, Capital World Investors raised its holdings in shares of Danaher by 32.7% during the 4th quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock worth $1,460,215,000 after acquiring an additional 1,566,658 shares during the period. Institutional investors and hedge funds own 79.05% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Evercore ISI cut their price objective on shares of Danaher from $240.00 to $230.00 and set an "outperform" rating for the company in a research report on Tuesday, April 22nd. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Guggenheim reaffirmed a "buy" rating and set a $250.00 price target on shares of Danaher in a research report on Wednesday, April 23rd. Royal Bank Of Canada reiterated an "outperform" rating and issued a $250.00 price objective on shares of Danaher in a research report on Wednesday, April 23rd. Finally, Argus reduced their target price on Danaher from $260.00 to $240.00 in a research report on Wednesday, April 23rd. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, Danaher presently has an average rating of "Moderate Buy" and a consensus target price of $248.17.

Get Our Latest Research Report on DHR

Insiders Place Their Bets

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the transaction, the executive vice president now owns 15,179 shares in the company, valued at $3,005,442. The trade was a 51.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction on Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the sale, the chairman now owns 3,105,808 shares in the company, valued at $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is owned by company insiders.

Danaher Stock Down 0.7%

Shares of NYSE DHR traded down $1.39 during midday trading on Thursday, hitting $194.36. The company's stock had a trading volume of 3,236,239 shares, compared to its average volume of 3,488,121. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05. The firm has a market capitalization of $139.10 billion, a price-to-earnings ratio of 37.74, a price-to-earnings-growth ratio of 2.73 and a beta of 0.77. The business's fifty day simple moving average is $193.74 and its two-hundred day simple moving average is $210.00. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, beating the consensus estimate of $1.62 by $0.26. Danaher had a net margin of 15.81% and a return on equity of 10.80%. The company had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. On average, equities analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.66%. Danaher's payout ratio is 24.85%.

Danaher Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Read More

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Should You Invest $1,000 in Danaher Right Now?

Before you consider Danaher, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.

While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The Drone Industry Is About to 10X—Here’s How to Profit
Why AMD Stock Beats NVIDIA Right Now
Oil Spikes Amid Rising Warfare: 3 Stocks to Watch Now

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines